Rediscover your everyday
Individual results may vary
Amalia, an artist and Alnylam Patient Ambassador, shares her AHP and treatment journey
Don't wait for the next attack.
Attack the disease.
GIVLAARI is given once a month as a subcutaneous injection (under the skin) by a healthcare professional.
Reduces levels of toxins
GIVLAARI reduces levels of aminolevulinic acid (ALA) and porphobilinogen (PBG), toxins associated with attacks and other AHP symptoms.
Fewer porphyria attacks
In a 6-month study, on average, patients with AHP had their attacks reduced by 70% after receiving GIVLAARI compared with those receiving placebo.
Fewer days of hemin use
In a 6-month study, on average, patients with AHP had 70% fewer days of hemin use after receiving GIVLAARI compared with those receiving placebo.
Most common side effects
In a 6-month study, the most common side effects of GIVLAARI were nausea and injection site reactions.
After the 6-month study, patients with AHP experienced fewer attacks with continued treatment.
Attacks were defined as those that required hospitalization, urgent healthcare visit, or intravenous (IV) hemin administration at home.